Mainz Biomed N.V. (QUCY)
NASDAQ: QUCY · Real-Time Price · USD
0.502
-0.038 (-7.04%)
At close: Apr 28, 2026, 4:00 PM EDT
0.650
+0.148 (29.57%)
After-hours: Apr 28, 2026, 5:37 PM EDT
Mainz Biomed Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 0.54 | 0.89 | 0.9 | 0.53 | 0.58 | |
| Revenue Growth (YoY) | -39.92% | -0.17% | 69.00% | -8.22% | 16.98% | |
| Cost of Revenue | 0.15 | 0.32 | 0.39 | 0.35 | 0.4 | |
| Gross Profit | 0.39 | 0.57 | 0.51 | 0.18 | 0.18 | |
| Selling, General & Admin | 8.93 | 13.23 | 17.56 | 21.61 | 9.42 | |
| Research & Development | 4.96 | 5.84 | 9.59 | 5.02 | 0.48 | |
| Operating Expenses | 13.89 | 19.07 | 27.15 | 26.63 | 9.9 | |
| Operating Income | -13.5 | -18.5 | -26.64 | -26.44 | -9.72 | |
| Interest Expense | -0.37 | -0.95 | -0.56 | -0.29 | -0.34 | |
| Other Non Operating Income (Expenses) | 0.44 | 0.1 | 0.2 | 0.35 | 0.39 | |
| EBT Excluding Unusual Items | -13.43 | -19.34 | -27.01 | -26.39 | -9.67 | |
| Merger & Restructuring Charges | - | -0.28 | - | - | -2.02 | |
| Gain (Loss) on Sale of Assets | -0.16 | 0.08 | - | - | - | |
| Asset Writedown | -2.64 | - | - | - | - | |
| Other Unusual Items | 0.02 | -2.05 | 0.71 | - | - | |
| Pretax Income | -16.21 | -21.6 | -26.3 | -26.39 | -11.69 | |
| Net Income | -16.21 | -21.6 | -26.3 | -26.39 | -11.69 | |
| Net Income to Common | -16.21 | -21.6 | -26.3 | -26.39 | -11.69 | |
| Shares Outstanding (Basic) | 6 | 1 | 0 | 0 | 0 | |
| Shares Outstanding (Diluted) | 6 | 1 | 0 | 0 | 0 | |
| Shares Change (YoY) | 508.38% | 142.75% | 14.73% | 96.34% | 28.60% | |
| EPS (Basic) | -2.70 | -21.91 | -64.76 | -74.55 | -64.85 | |
| EPS (Diluted) | -2.70 | -21.91 | -64.76 | -74.55 | -64.85 | |
| Free Cash Flow | -10.98 | -17.43 | -23.14 | -15.43 | -3.24 | |
| Free Cash Flow Per Share | -1.83 | -17.69 | -56.98 | -43.59 | -17.96 | |
| Gross Margin | 72.58% | 64.31% | 56.92% | 34.38% | 30.76% | |
| Operating Margin | -2513.37% | -2068.93% | -2975.47% | -4990.60% | -1684.36% | |
| Profit Margin | -3018.31% | -2415.99% | -2936.50% | -4979.90% | -2024.79% | |
| Free Cash Flow Margin | -2044.54% | -1950.15% | -2583.83% | -2911.63% | -560.67% | |
| EBITDA | -12.88 | -17.8 | -26.07 | -26.06 | -9.65 | |
| D&A For EBITDA | 0.62 | 0.7 | 0.57 | 0.38 | 0.07 | |
| EBIT | -13.5 | -18.5 | -26.64 | -26.44 | -9.72 | |
| Revenue as Reported | 0.54 | 0.89 | 0.9 | 0.53 | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.